Butylated Hydroxyanisole vs Partially Hydrogenated Oils: which is worse?

What is Butylated Hydroxyanisole?

Butylated hydroxyanisole (BHA) is a synthetic phenolic antioxidant preservative derived from petroleum (see also bha entry). It is a mixture of 2-BHA and 3-BHA isomers, used to prevent oxidative rancidity in fats, oils, and fat-containing foods. Chemical formula C11H16O2.

What is Partially Hydrogenated Oils?

Partially hydrogenated oils (PHOs) are vegetable oils that have been treated with hydrogen gas in the presence of a catalyst to make them semi-solid at room temperature. This process creates artificial trans fatty acids (trans fats) as a byproduct. They were developed in the early 20th century as a cheaper, longer-lasting alternative to lard and butter.

Documented risks

Butylated Hydroxyanisole: IARC classifies BHA as Group 2B (possible human carcinogen) based on forestomach tumor studies in rodents at high doses. The NTP lists it as 'reasonably anticipated to be a human carcinogen.' EFSA's 2012 review found endocrine-disrupting potential. Japan banned it for food use. The FDA permits it at 0.02% of fat content. Concerns about estrogen-receptor interaction have been documented in animal studies. Contact dermatitis from cosmetic use is reported.

Partially Hydrogenated Oils: Artificial trans fats (from PHOs) have the most well-established cardiovascular harm of any food ingredient ever banned. Multiple large meta-analyses have confirmed that trans fat consumption increases LDL ('bad') cholesterol, decreases HDL ('good') cholesterol, increases inflammatory markers, and significantly raises cardiovascular disease risk. The Harvard Nurses' Health Study and other landmark prospective studies in the 1990s identified trans fat as uniquely harmful — worse than saturated fat in its cardiovascular effects. A 2006 NEJM meta-analysis by Mozaffarian et al. estimated that eliminating artificial trans fats from the US diet could prevent 72,000 to 228,000 heart attacks per year and 30,000 to 100,000 coronary heart disease deaths annually. The WHO estimates that industrially produced trans fats cause over 500,000 cardiovascular deaths per year globally. The FDA revoked PHOs' GRAS status in 2015 based on this evidence, with compliance by 2018. Denmark banned artificial trans fats in 2003, the first country to do so, and observed a dramatic reduction in cardiovascular mortality in subsequent years.